V Siguret

Summary

Country: France

Publications

  1. ncbi request reprint [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients]
    V Siguret
    Laboratoire d Hematologie, Hopital Charles Foix, 7, avenue de la Republique, 94205 Ivry sur Seine cedex, France
    Rev Med Interne 25:271-4. 2004
  2. ncbi request reprint Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days
    V Siguret
    Laboratoire d Hematologie, H pital Charles Foix, Ivry Seine, France
    Thromb Haemost 84:800-4. 2000
  3. ncbi request reprint Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen
    Virginie Siguret
    Hematology Laboratory, Charles Foix Teaching Hospital AP HP, Paris, France
    Am J Med 118:137-42. 2005
  4. ncbi request reprint Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004
    Virginie Siguret
    Laboratoire d Hématologie and Unité de Gériatrie Aiguë, Hôpital Charles Foix University Hospital of Paris, Ivry Seine, France
    Curr Opin Pulm Med 10:366-70. 2004
  5. ncbi request reprint [Monitoring of tinzaparin in a ten day treatment dose in elderly patients]
    E Pautas
    Unité gériatrique aiguë, Hopital Charles Foix, avenue de la Republique, 94205 Ivry sur Seine, France
    Rev Med Interne 22:120-6. 2001
  6. doi request reprint Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes
    C Moreau
    Universite Paris Descartes, Paris, France
    J Thromb Haemost 9:711-8. 2011
  7. doi request reprint Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
    E Pautas
    Universite Paris Descartes, Paris, France
    Clin Pharmacol Ther 87:57-64. 2010
  8. doi request reprint No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy
    V Siguret
    Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    J Thromb Haemost 9:1966-72. 2011
  9. ncbi request reprint Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years old
    A F Le Blanche
    Department of Radiology and Medical Imaging, Charles Foix Jean Rostand University Hospital Group, Ivry sur Seine, France
    Angiology 50:873-82. 1999
  10. ncbi request reprint [Evaluation of a new automatic hematological system: the Advia 70 (Bayer-Diagnostics)]
    V Siguret
    Laboratoire d Hematologie, GH Charles Foix Jean Rostand AP HP, Ivry sur Seine, France
    Ann Biol Clin (Paris) 60:541-8. 2002

Collaborators

Detail Information

Publications15

  1. ncbi request reprint [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients]
    V Siguret
    Laboratoire d Hematologie, Hopital Charles Foix, 7, avenue de la Republique, 94205 Ivry sur Seine cedex, France
    Rev Med Interne 25:271-4. 2004
    ..The aim of our purpose was to investigate whether a genetic factor, such as cyp2c9 genotype, does influence the warfarin maintenance dose in very elderly patients...
  2. ncbi request reprint Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days
    V Siguret
    Laboratoire d Hematologie, H pital Charles Foix, Ivry Seine, France
    Thromb Haemost 84:800-4. 2000
    ..Neither dose adjustment, nor serial anti-Xa activity monitoring seems to be required in patients with creatinine clearance above 20 mL/min during the first ten day treatment...
  3. ncbi request reprint Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen
    Virginie Siguret
    Hematology Laboratory, Charles Foix Teaching Hospital AP HP, Paris, France
    Am J Med 118:137-42. 2005
    ..We conducted a prospective multicenter study to evaluate the accuracy and safety of this regimen...
  4. ncbi request reprint Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004
    Virginie Siguret
    Laboratoire d Hématologie and Unité de Gériatrie Aiguë, Hôpital Charles Foix University Hospital of Paris, Ivry Seine, France
    Curr Opin Pulm Med 10:366-70. 2004
    ..Little evidence is available to assess the risk/benefit ratio of low molecular weight heparins used at therapeutic dosages in elderly patients with or without renal insufficiency in normal clinical practice...
  5. ncbi request reprint [Monitoring of tinzaparin in a ten day treatment dose in elderly patients]
    E Pautas
    Unité gériatrique aiguë, Hopital Charles Foix, avenue de la Republique, 94205 Ivry sur Seine, France
    Rev Med Interne 22:120-6. 2001
    ..Thus, we conducted a prospective study to determine whether tinzaparin, administered subcutaneously at treatment dose (175 anti-Xa IU/kg) once daily for 10 days, does accumulate in patients older than 70 years of age...
  6. doi request reprint Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes
    C Moreau
    Universite Paris Descartes, Paris, France
    J Thromb Haemost 9:711-8. 2011
    ..Initiating warfarin is challenging in frail elderly patients because of low-dose requirements and interindividual variability...
  7. doi request reprint Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
    E Pautas
    Universite Paris Descartes, Paris, France
    Clin Pharmacol Ther 87:57-64. 2010
    ..8; 95% confidence interval, 2.73-60.0). In this special population of frail elderly patients with multiple comorbidities and polypharmacy, we demonstrated the main impact of genetic factors on warfarin response...
  8. doi request reprint No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy
    V Siguret
    Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    J Thromb Haemost 9:1966-72. 2011
    ..In the elderly, concerns have been raised regarding the risk of accumulation of low molecular weight heparins, owing to their renal elimination. Although data exist for tinzaparin, they are observational...
  9. ncbi request reprint Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years old
    A F Le Blanche
    Department of Radiology and Medical Imaging, Charles Foix Jean Rostand University Hospital Group, Ivry sur Seine, France
    Angiology 50:873-82. 1999
    ..In inpatients above 70, an ELISA plasma D-dimer value smaller than 750 ng/mL is a rapid reliable noninvasive means to rule out lower limb DVT, if color flow Doppler ultrasound is not available on site...
  10. ncbi request reprint [Evaluation of a new automatic hematological system: the Advia 70 (Bayer-Diagnostics)]
    V Siguret
    Laboratoire d Hematologie, GH Charles Foix Jean Rostand AP HP, Ivry sur Seine, France
    Ann Biol Clin (Paris) 60:541-8. 2002
    ..Finally, we evaluated the leukocyte differential flags on 72 patients samples with abnormal cells, using the blood smear examination as the reference method. In conclusion, the Advia 70 can be used in private and hospital laboratories...
  11. ncbi request reprint [Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey]
    V Siguret
    Laboratoire d Hematologie, G H Charles Foix Jean Rostand AP HP, Ivry sur Seine 94
    Presse Med 32:972-7. 2003
    ..The International Normalized Ratio (INR) should be well controlled and its stabilisation within the therapeutic range help to prevent the haemorrhagic complications...
  12. ncbi request reprint Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days
    I Gouin-Thibault
    J Thromb Haemost 1:2694-5. 2003
  13. ncbi request reprint [Prescribing guidance pocket chart on the initiation of warfarin therapy in a geriatric hospital: a useful but challenging tool]
    V Siguret
    Laboratoire d Hematologie, Groupe Hospitalier Charles Foix Jean Rostand AP HP, Ivry sur Seine
    Ann Biol Clin (Paris) 64:245-51. 2006
    ..Finally, the reasons for non-adherence to the recommendations were analyzed. This study illustrates an assessment of practice in an health care institution...
  14. ncbi request reprint [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy]
    V Siguret
    Service d Hématologie Hémostase, INSERM U765, Faculte des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes Paris V, France
    Pathol Biol (Paris) 55:295-8. 2007
    ..Predicting models of warfarin maintenance dosage taking into account these individual parameters are currently developed...
  15. ncbi request reprint [Oral anticoagulants in the elderly]
    M Debray
    Département de Médecine Gériatrique et Communautaire, Centre Hospitalier Universitaire, 38043 Cedex 09, Grenoble, France
    Rev Med Interne 24:107-17. 2003
    ..Finally, prescribers education supports must insist on the early course of therapy that is at higher risk of bleeding...